<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alternative therapy for young patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (sAML) lacking a suitable donor </plain></SENT>
<SENT sid="1" pm="."><plain>We report the results for 79 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML transplanted with autologous marrow in first complete remission (CR) </plain></SENT>
<SENT sid="2" pm="."><plain>Within the total group of 79, a cohort of 55 patients for whom the duration of first CR was known were compared with a matched control group of 110 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The 2-year survival, disease-free survival (DFS), and relapse rates for the 79 patients transplanted in first CR were 39%, 34%, and 64%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The relapse risk was greater than 55% for <z:hpo ids='HP_0000001'>all</z:hpo> stages and <z:hpo ids='HP_0000001'>all</z:hpo> disease categories </plain></SENT>
<SENT sid="5" pm="."><plain>Patients younger than 40 years had a significantly (P = .04) better DFS (39%) than patients older than 40 years (25%) </plain></SENT>
<SENT sid="6" pm="."><plain>The DFS at 2 years was 28% for the cohort of 55 patients transplanted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML and 51% for those transplanted for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = .025) </plain></SENT>
<SENT sid="7" pm="."><plain>Relapse rates were 69% for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML and 40% for those with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = .007) </plain></SENT>
<SENT sid="8" pm="."><plain>ABMT for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> results in a lower DFS when compared with similarly treated patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> due to a higher relapse rate </plain></SENT>
<SENT sid="9" pm="."><plain>The DFS of 28% for these patients suggests that autotransplantation may be a valuable therapy for this disease </plain></SENT>
<SENT sid="10" pm="."><plain>The low treatment-related mortality rate of less than 10% supports the view that sufficient numbers of hematopoietic stem cells are present in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to allow adequate repopulation after autologous stem-cell transplantation </plain></SENT>
</text></document>